Pegvisomant and cabergoline combination therapy in acromegaly

Pituitary

Volumn 16, Issue 1, 2013, Pages 101-108

  Bernabeu, I ^a,b   Alvarez Escola C ^c,d   Paniagua, A E ^e   Lucas, T ^d,f   Pavon I ^g,h   Cabezas Agricola J M ^a,b   Casanueva, F F ^a,b   Marazuela, M ^d,i  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^e HOSPITAL INFANTA CRISTINA   (Spain)

^f HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^g HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^h UNIVERSIDAD EUROPEA DE MADRID   (Spain)

ⁱ Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa   (Spain)

Author keywords

Acromegaly; Cabergoline; Pegvisomant; Somatostatin analogues

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CABERGOLINE; CREATININE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; LACTATE DEHYDROGENASE; PEGVISOMANT; PROLACTIN; SOMATOMEDIN;

ACROMEGALY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY WEIGHT; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84873712361     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-012-0382-z     Document Type: Article

References (34)

1. Chanson P, Salenave S, Kamenicky P, Cazabat L, Young J (2009) Pituitary tumours: acromegaly. Best Pract Res Clin Endocrinol Metab 23(5):555-574
2. Murray RD, Melmed S (2008) A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 93(8):2957-2968
3. Trainer PJ (2009) ACROSTUDY: the first 5 years. Eur J Endocrinol 161(1):S19-S24
4. Marazuela M, Lucas T, Alvarez-Escola C, Puig-Domingo M, de la Torre NG, de Miguel-Novoa P, Duran-Hervada A, Manzanares R, Luque-Ramirez M, Halperin I, Casanueva FF, Bernabeu I (2009) Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy. Eur J Endocrinol 160(4):535-542
5. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ (2002) Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 23(5):623-646
6. Marazuela M, Paniagua AE, Gahete MD, Lucas T, Alvarez-Escola C, Manzanares R, Cameselle-Teijeiro J, Luque-Ramirez M, Luque RM, Fernandez-Rodriguez E, Castano JP, Bernabeu I (2011) Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study. J Clin Endocrinol Metab 96(2):E251-E259
7. Jimenez C, Burman P, Abs R, Clemmons DR, Drake WM, Hutson KR, Messig M, Thorner MO, Trainer PJ, Gagel RF (2008) Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. Eur J Endocrinol 159(5):517-523
8. Buchfelder M, Weigel D, Droste M, Mann K, Saller B, Brubach K, Stalla GK, Bidlingmaier M, Strasburger CJ (2009) Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. Eur J Endocrinol 161(1):27-35
9. Hodish I, Barkan A (2008) Long-term effects of pegvisomant in patients with acromegaly. Nat Clin Pract Endocrinol Metab 4(6):324-332
10. Moore DJ, Adi Y, Connock MJ, Bayliss S (2009) Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation. BMC Endocr Disord 9:20
11. Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ (2007) Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 92(12):4598-4601
12. Neggers SJ, de Herder WW, Janssen JA, Feelders RA, van der Lely AJ (2009) Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol 160(4):529-533
13. Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA, van der Lely AJ (2005) Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365(9471):1644-1646
14. Trainer PJ, Ezzat S, D'Souza GA, Layton G, Strasburger CJ (2009) A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf) 71(4):549-557
15. Neggers SJ, van Aken MO, de Herder WW, Feelders RA, Janssen JA, Badia X, Webb SM, van der Lely AJ (2008) Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab 93(10):3853-3859
16. Liuzzi A, Chiodini PG, Botalla L, Cremascoli G, Muller EE, Silvestrini F (1974) Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration. J Clin Endocrinol Metab 38(5):910-912
17. An JJ, Cho SR, Jeong DW, Park KW, Ahn YS, Baik JH (2003) Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells. Mol Cell Endocrinol 206(1-2):49-62
18. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 331(14):904-909
19. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A (1998) Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 83(2):374-378
20. Sandret L, Maison P, Chanson P (2011) Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab 96(5):1327-1335
21. Roemmler J, Steffin B, Gutt B, Schneider HJ, Sievers C, Bidlingmaier M, Schopohl J (2010) The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment. Growth Horm IGF Res 20(5):338-344
22. Colao A, Auriemma RS, Lombardi G, Pivonello R (2011) Resistance to somatostatin analogs in acromegaly. Endocr Rev 32(2):247-271
23. Castinetti F, Morange I, Dufour H, Regis J, Brue T (2009) Radiotherapy and radiosurgery in acromegaly. Pituitary 12(1):3-10
24. Freda PU, Reyes CM, Nuruzzaman AT, Sundeen RE, Khandji AG, Post KD (2004) Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors. Pituitary 7(1):21-30
25. Moyes VJ, Metcalfe KA, Drake WM (2008) Clinical use of cabergoline as primary and adjunctive treatment for acromegaly. Eur J Endocrinol 159(5):541-545
26. Verhelst JA, Abrams PJ, Abs R (2008) Remission of acromegaly following long-term therapy with cabergoline: report of two cases. Pituitary 11(1):103-107
27. Higham CE, Atkinson AB, Alywin S, Martin NM, Moyes VJ, Newell-Price J, Trainer PJ (2009) A prospective clinical trial of combined cabergoline and pegvisomant treatment in patients with active acromegaly (Abstract). 91st annual meeting of the endocrine society, 10-13 June 2009, Washington
28. Cozzi R, Attanasio R, Lodrini S, Lasio G (2004) Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 61(2):209-215
29. Cozzi R, Attanasio R, Barausse M, Dallabonzana D, Orlandi P, Da Re N, Branca V, Oppizzi G, Gelli D (1998) Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur J Endocrinol 139(5):516-521
30. Goldenberg N, Barkan A (2007) Factors regulating growth hormone secretion in humans. Endocrinol Metab Clin North Am 36(1):37-55
31. Parkinson C, Burman P, Messig M, Trainer PJ (2007) Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. J Clin Endocrinol Metab 92(1):190-195
32. Lamberts SW, Klijn JG, van Vroonhoven CC, Stefanko SZ, Liuzzi A (1983) The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly. Acta Endocrinol (Copenh) 103(4):446-450
33. Lamberts SW, Liuzzi A, Chiodini PG, Verde S, Klijn JG, Birkenhager JC (1982) The value of plasma prolactin levels in the prediction of the responsiveness of growth hormone secretion to bromocriptine and TRH in acromegaly. Eur J Clin Invest 12(2):151-155
34. Sherlock M, Fernandez-Rodriguez E, Alonso AA, Reulen RC, Ayuk J, Clayton RN, Holder G, Sheppard MC, Bates A, Stewart PM (2009) Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues. J Clin Endocrinol Metab 94(4):1255-1263